SCHWAEBLE, HANS-WILHELM,DUDLER, THOMAS A.,TEDFORD, CLARK E.,PARENT, JAMES B.,DEMOPULOS, GREGORY A.
申请号：
CA2777845
公开号：
CA2777845C
申请日:
2010.10.15
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
